Medical device and MedTech insights, news, tips and more

QT Medical® Announces Completion of Series B Financing of $12 Million

September 27, 2023


QT Medical, Inc., a medtech company focused on cardiac care technology, announced today that it raised $12 million in Series B financing. This funding will accelerate QT Medical’s market penetration, global expansion, product pipeline development, and long-term strategic planning.

QT Medical aims to provide improved cardiac devices and services to revolutionize the care of patients with heart disease. Its flagship product, the Personal Cardiac Assistant (PCA 500)™, is the only hospital-grade, resting 12-lead ECG device cleared by the FDA and CE marked for both professional and patient use. This device is wireless, digital, cloud managed, weighs 2.3 ounces, and is less than 3 inches square in size. It is smaller than a deck of cards, fits in a shirt pocket or a mailing envelope, and utilizes phone/tablet apps. The proprietary single-use, self-adhesive sensor replaces traditional electrodes/wires. PCA 500 is currently being used across the continuum of care including on commercial flights for inflight medical emergencies, in schools for detecting student athlete risks for sudden cardiac arrest, in clinical trials for cardiac safety testing, as well as in urgent care centers, nursing homes, hospitals, digital health clinics, and by thousands of patients at home for self-care supervised by physicians.

Resting 12-lead ECG is the most used medical test for screening, diagnosing, and monitoring heart disease. However, traditional 12-lead ECG machines are bulky (requiring wheeled carts for mobility), inefficient, and can be used only by trained professionals. Single-lead ECGs, such as Apple Watch, may be useful for arrhythmia detection, but unlike 12-lead ECGs, it cannot provide a comprehensive view of the heart for potential coronary artery disease, cardiomyopathy, myocarditis, and many other cardiac and non-cardiac conditions.

“Our vision is to improve heart health around the world by empowering people with new medical technologies which promote improved personalized care. The Series B funding will accelerate our process towards achieving this goal,” said Ruey-Kang Chang, MD, Chief Executive Officer of QT Medical.

Series B Financing
The Series B financing was led by CDIB Capital and Taiwania Capital. Cathay Capital, BE Capital, TMU Biomed, and existing investor, Quanta Computer, also joined the Series B round.
 “This financing round is crucial for us to accelerate growth and develop long-term strategies. We are changing the performance and delivery of cardiac care services by healthcare professionals and bringing this technology to millions of patients with heart disease for self-care at home,” Chang said.

For more information, please visit

About CDIB Capital
Formerly called China Development Industrial Bank, CDIB Capital was founded in 1959 and officially renamed with this underlying business transformation in March 2017. This evolution is underpinned by the goal of becoming the leading private equity and venture capital fund manager in the Asia-Pacific region.

About Taiwania Capital
Taiwania Capital is a venture capital firm founded in August 2017 by the National Development Fund of the Executive Yuan of Taiwan ROC and private enterprises. The mission is to establish a partnership with companies worldwide and boost Taiwan’s economic growth.

See Full Press Release at the Source: QT Medical® Announces Completion of Series B Financing of $12 Million

Press Release by: QT Medical

Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.